Ignite Creation Date:
2025-12-24 @ 11:47 AM
Ignite Modification Date:
2026-01-04 @ 2:03 PM
Study NCT ID:
NCT00356161
Status:
UNKNOWN
Last Update Posted:
2006-07-25
First Post:
2006-07-24
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
HAI Via Interventionally Implanted Port Catheter Systems
Sponsor:
Charite University, Berlin, Germany
Organization:
Study Overview
Official Title:
Open One-Arm Therapy Optimizing Trial on Regional Chemotherapy of the Liver Through an Interventionally Implanted A.Hepatica Port System in Patients With Liver Metastases or Primary Liver Neoplasms.
Status:
UNKNOWN
Status Verified Date:
2006-07
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Procedures to provide interventional implantation of a port catheter system into the hepatic artery and adjacent regional chemotherapy of the liver are optimized in the scope of an open, single-arm trial in patients with metastases and cancers confined to the liver. The primary objective is the improvement of indication, implantation procedure, and regional chemotherapy. Secondary objectives are port patency, comparison of complications with a historical collective of patients provided with a surgical hepatic arterial port device (colorectal cancer patients only), progression free and overall survival, efficacy of maintaining regional chemotherapy with 5-FU in combination with systemic treatment in patients with extrahepatic progression, quality of life.
Detailed Description:
Inclusion criteria:
* histologically confirmed hepatic cancer without symptomatic extrahepatic manifestation.
* non-resectable disease or hepatic resection or ablation in between the past 8 weeks.
* measurable disease (at least before hepatic resection)
* Karnofsky performance status =\> 70%, or ECOG status 0-2
* \>18 years of age
* life expectancy \> 6 months
* compliance of the patient
* written informed consent
Exclusion criteria:
* second neoplasia within the past 3 years, except for non-melanotic skin cancer, adequately treated Ca in situ of cervix uteri, or adequately resected second colorectal cancer (in patients with liver metastases of colorectal cancer)
* symptomatic extrahepatic disease, in particular disseminated bone metastases, brain metastases
* liver cirrhosis with portal hypertension, active hepatitis B or C, previous percutaneous radiotherapy of the liver
* active infection
* history of gastric or duodenal ulcer
* symptomatic or uncontrolled peripheral arterial occlusive disease, history of stenosis of the renal artery.
* history of dilatative cardiomyopathy, vitium of mitral or aortic valve, persisting foramen ovale, atrial fibrillation
* artificial heart valve or vascular
* history of diabetic microangiopathy
* uncontrolled hyperthyriodism
* other severe concomitant disease (heart failure \>NYHA 2°, respiratory failure, renal failure \>stage2, liver failure (TPZ \<50%).
* inherited or acquired immunodeficiency syndrome
* contraindication against 5-FU
* pregnancy and nursing, no contraception
* limited contractual capability.
After enrollment, an a port catheter catheter system is interventionally implanted into the hepatic artery and the patient is scheduled for regional chemotherapy according one out of 8 pre-defined chemotherapy schedules. All regimens are based on 5-fluorouracil and leucovorin, and optionally contain intraarterial mitomycin, oxaliplatin, or additional intravenous irinotecan.
Patients are followed up and evaluated for primary and secondary endpoints. After the inclusion of 50 patients treated and follow up at our institution, the study population has been extended to 100 patients in 8/2004.
* histologically confirmed hepatic cancer without symptomatic extrahepatic manifestation.
* non-resectable disease or hepatic resection or ablation in between the past 8 weeks.
* measurable disease (at least before hepatic resection)
* Karnofsky performance status =\> 70%, or ECOG status 0-2
* \>18 years of age
* life expectancy \> 6 months
* compliance of the patient
* written informed consent
Exclusion criteria:
* second neoplasia within the past 3 years, except for non-melanotic skin cancer, adequately treated Ca in situ of cervix uteri, or adequately resected second colorectal cancer (in patients with liver metastases of colorectal cancer)
* symptomatic extrahepatic disease, in particular disseminated bone metastases, brain metastases
* liver cirrhosis with portal hypertension, active hepatitis B or C, previous percutaneous radiotherapy of the liver
* active infection
* history of gastric or duodenal ulcer
* symptomatic or uncontrolled peripheral arterial occlusive disease, history of stenosis of the renal artery.
* history of dilatative cardiomyopathy, vitium of mitral or aortic valve, persisting foramen ovale, atrial fibrillation
* artificial heart valve or vascular
* history of diabetic microangiopathy
* uncontrolled hyperthyriodism
* other severe concomitant disease (heart failure \>NYHA 2°, respiratory failure, renal failure \>stage2, liver failure (TPZ \<50%).
* inherited or acquired immunodeficiency syndrome
* contraindication against 5-FU
* pregnancy and nursing, no contraception
* limited contractual capability.
After enrollment, an a port catheter catheter system is interventionally implanted into the hepatic artery and the patient is scheduled for regional chemotherapy according one out of 8 pre-defined chemotherapy schedules. All regimens are based on 5-fluorouracil and leucovorin, and optionally contain intraarterial mitomycin, oxaliplatin, or additional intravenous irinotecan.
Patients are followed up and evaluated for primary and secondary endpoints. After the inclusion of 50 patients treated and follow up at our institution, the study population has been extended to 100 patients in 8/2004.
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?: